Justin Kim

GW Pharmaceuticals plc (NASDAQ: GWPH) Epidiolex drug and earlier-stage programs Sativex and CBDV will represent major catalysts for the stock in the near-term, in Cantor Fitzgerald's view.  The Analyst Analyst Elemer Piros reiterated an Overweight on GW Pharmaceuticals with a $211 price...

Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) earned another bullish analyst this week with a positive rating from Cantor Fitzgerald. The coverage comes with a valuation that implies 459-percent upside. The Rating Analyst Elemer Piros initiated coverage of Galmed Pharmaceuticals with an...

Following the release of briefing documents for Aerie Pharmaceuticals Inc (NASDAQ: AERI)'s Rhopressa's upcoming Adcom meeting, Cantor Fitzgerald said the news was good, with no surprises. The Adcom meeting is scheduled on October 13, 2017. Reviewing all the data and the recent briefing documents...

Following Intercept Pharmaceuticals Inc (NASDAQ: ICPT)'s strong second-quarter results and meaningful Ocaliva, or OCA, revenue growth, Cantor Fitzgerald maintains its Underweight rating on the shares of the company. However, the firm raised its price target for the shares from $60 to $69. Strong Q2...

Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) was at its volatile best all this week. After a 14-percent gain Monday, the stock pulled back slightly Tuesday and retreated by less than 2 percent Wednesday. It rallied over 10 percent Thursday, only to slip by about 7 percent Friday amid the Bellicum...

Despite confirming third-quarter catalysts and progress throughout its development pipeline, Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE)’s first-quarter financial report didn’t impress investors. The company conceded an 8.3-percent stock decline Tuesday even as it boasts a 22-percent...

Cantor Fitzgerald reiterated its Buy rating and $21 as the price target for Abeona Therapeutics Inc (NASDAQ: ABEO) shares. The firm's move comes on the heels of the company announcing enrollment of patients in phase 2A study following the positive results from its Phase one trial. Analysts Elemer...